(Reuters) - Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an...
(Reuters) - Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an...
